Journal of Gastrointestinal Surgery

, Volume 20, Issue 1, pp 93–103 | Cite as

Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer

  • Francesca Dimou
  • Helmneh Sineshaw
  • Abhishek D. Parmar
  • Nina P. Tamirisa
  • Ahmedin Jemal
  • Taylor S. Riall
2015 SSAT Plenary Presentation



Pancreatic cancer is considered a systemic disease at presentation. Therefore, multimodality therapy with surgical resection and chemotherapy is the standard of care for locoregional disease. We described treatment patterns and time trends with regard to age and treatment center in the receipt of multimodality therapy.


We used the National Cancer Data Base to identify patients ≥18 years old with stage I and II pancreatic adenocarcinoma. Treatment was defined as no treatment, resection only, chemotherapy only, or multimodality therapy, which consisted of both chemotherapy (neoadjuvant or adjuvant) and resection. Trends in the receipt and type of treatment were compared.


Of 39,441 patients, 22.8 % of patients received no treatment, 18.5 % received chemotherapy only, 23.0 % underwent surgical resection alone, and 35.8 % of patients received multimodality therapy. Receipt of multimodality therapy increased from 31.3 % in 2004 to 37.9 % in 2011 (p < 0.0001). Patients >55 years were less likely to receive multimodality therapy (56–64 years: OR 0.83, 95 % CI 0.78–0.89; 65–75: OR 0.60, 95 % CI 0.55–0.65; ≥76: OR 0.17, 95 % CI 0.16–0.19 compared to patients 18–55). Compared to community hospitals, patients treated at an NCI-designated center were more likely to receive multimodality therapy (OR 1.62, 95 % CI 1.46–1.81) and, if they received multimodality therapy, delivery of chemotherapy in the neoadjuvant compared to adjuvant setting (OR 2.82, 95 % CI 2.00–3.98).


Despite increased use of multimodality therapy, it remains underutilized in all patients and especially in older patients. Receipt of multimodality therapy and neoadjuvant therapy is highly dependent on treatment at NCI-designated cancer centers.


Pancreatic cancer Multimodality therapy Pancreatic adenocarcinoma Pancreas Therapy Treatment 



Supported by grants from the Cancer Prevention Research Institute of Texas Grant # RP140020 , UTMB Clinical and Translational Science Award #UL1TR000071, NIH T-32 Grant # 5T32DK007639, and AHRQ Grant # 1R24HS022134.


  1. 1.
    Siegel, R., D. Naishadham, and A. Jemal, Cancer statistics, 2013. CA Cancer J Clin, 2013. 63(1): p. 11-30.PubMedCrossRefGoogle Scholar
  2. 2.
    Sugiura, T., K. Uesaka, K. Mihara, et al., Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer. Surgery, 2013. 154(5): p. 1078-86.PubMedCrossRefGoogle Scholar
  3. 3.
    Raut, C.P., J.F. Tseng, C.C. Sun, et al., Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg, 2007. 246(1): p. 52-60.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Hernandez, J., J. Mullinax, W. Clark, et al., Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins. Ann Surg, 2009. 250(1): p. 76-80.PubMedCrossRefGoogle Scholar
  5. 5.
    Smaglo, B.G. and M.J. Pishvaian, Postresection chemotherapy for pancreatic cancer. Cancer J, 2012. 18(6): p. 614-23.PubMedCrossRefGoogle Scholar
  6. 6.
    Kooby, D.A., T.W. Gillespie, Y. Liu, et al., Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Ann Surg Oncol, 2013. 20(11): p. 3634-42.PubMedCrossRefGoogle Scholar
  7. 7.
    Mayo, S.C., D.F. Austin, B.C. Sheppard, et al., Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis. Cancer, 2010. 116(12): p. 2932-40.PubMedCrossRefGoogle Scholar
  8. 8.
    Kosuge, T., T. Kiuchi, K. Mukai, et al., A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol, 2006. 36(3): p. 159-65.PubMedCrossRefGoogle Scholar
  9. 9.
    Cooper, A.B., H.M. Holmes, J.K. des Bordes, et al., Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer. J Am Coll Surg, 2014. 219(1): p. 111-20.PubMedCrossRefGoogle Scholar
  10. 10.
    Tzeng, C.W., H.S. Tran Cao, J.E. Lee, et al., Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg, 2014. 18(1): p. 16-24; discussion 24-5.PubMedCrossRefGoogle Scholar
  11. 11.
    Golcher, H., T.B. Brunner, H. Witzigmann, et al., Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: Results of the first prospective randomized phase II trial. Strahlenther Onkol, 2014.Google Scholar
  12. 12.
    Christians, K.K., S. Tsai, A. Mahmoud, et al., Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist, 2014. 19(3): p. 266-74.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Bilimoria, K.Y., D.J. Bentrem, C.Y. Ko, et al., National failure to operate on early stage pancreatic cancer. Ann Surg, 2007. 246(2): p. 173-80.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Vanderveen, K.A., R.J. Canter, D. Yin, et al., Factors affecting treatment delivery and outcomes of patients with early-stage pancreatic adenocarcinoma. Pancreas, 2011. 40(3): p. 480-2.PubMedCrossRefGoogle Scholar
  15. 15.
    Riall, T.S., C.M. Townsend, Jr., Y.F. Kuo, et al., Dissecting racial disparities in the treatment of patients with locoregional pancreatic cancer: a 2-step process. Cancer, 2010. 116(4): p. 930-9.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Murphy, M.M., J.P. Simons, S.C. Ng, et al., Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma. Ann Surg Oncol, 2009. 16(11): p. 2968-77.PubMedCrossRefGoogle Scholar
  17. 17.
    Cooper, A.B., A.D. Parmar, T.S. Riall, et al., Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates? J Gastrointest Surg, 2014.Google Scholar
  18. 18.
    Corsini, M.M., R.C. Miller, M.G. Haddock, et al., Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol, 2008. 26(21): p. 3511-6.PubMedCrossRefGoogle Scholar
  19. 19.
    Herman, J.M., M.J. Swartz, C.C. Hsu, et al., Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol, 2008. 26(21): p. 3503-10.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Yeo, C.J., R.A. Abrams, L.B. Grochow, et al., Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg, 1997. 225(5): p. 621-33; discussion 633-6.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Parmar, A.D., G.M. Vargas, N.P. Tamirisa, et al., Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. Surgery, 2014. 156(2): p. 280-9.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Simons, J.P., S.C. Ng, T.P. McDade, et al., Progress for resectable pancreatic [corrected] cancer?: a population-based assessment of US practices. Cancer, 2010. 116(7): p. 1681-90.PubMedCrossRefGoogle Scholar
  23. 23.
    Bilimoria, K.Y., A.K. Stewart, D.P. Winchester, et al., The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol, 2008. 15(3): p. 683-90.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Davila, J.A., E.Y. Chiao, J.C. Hasche, et al., Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer. Pancreas, 2009. 38(1): p. e18-25.PubMedCrossRefGoogle Scholar
  25. 25.
    Papalezova, K.T., D.S. Tyler, D.G. Blazer, 3rd, et al., Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol, 2012. 106(1): p. 111-8.PubMedCrossRefGoogle Scholar
  26. 26.
    Sener, S.F., A. Fremgen, H.R. Menck, et al., Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg, 1999. 189(1): p. 1-7.PubMedCrossRefGoogle Scholar
  27. 27.
    Bilimoria, K.Y., D.J. Bentrem, C.Y. Ko, et al., Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer, 2007. 110(6): p. 1227-34.PubMedCrossRefGoogle Scholar
  28. 28.
    Sen, N., S. Falk, and R.A. Abrams, Role of chemoradiotherapy in the adjuvant and neoadjuvant settings for resectable pancreatic cancer. Clin Oncol (R Coll Radiol), 2014. 26(9): p. 551-9.CrossRefGoogle Scholar
  29. 29.
    Merkow, R.P., K.Y. Bilimoria, J.S. Tomlinson, et al., Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg, 2014. 260(2): p. 372-7.PubMedCrossRefGoogle Scholar
  30. 30.
    Artinyan, A., D.A. Anaya, S. McKenzie, et al., Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer, 2011. 117(10): p. 2044-9.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2015

Authors and Affiliations

  • Francesca Dimou
    • 1
  • Helmneh Sineshaw
    • 3
  • Abhishek D. Parmar
    • 1
    • 2
  • Nina P. Tamirisa
    • 1
    • 2
  • Ahmedin Jemal
    • 3
  • Taylor S. Riall
    • 1
  1. 1.Department of SurgeryUniversity of Arizona, Banner-University Medical CenterTucsonUSA
  2. 2.Department of SurgeryUniversity of CaliforniaOaklandUSA
  3. 3.American Cancer SocietyAtlantaUSA

Personalised recommendations